LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.46
+1.65%Margins
Gross margin
98.1%
EBITDA margin
-751.4%
EBIT margin
-800.8%
Net margin
-755.1%
FCF margin
-713.0%
-54.4%
Return on equity
-49.7%
Return on assets
-57.7%
Return on invested capital
0.06x
Asset turnover
-$11.2M
Cash from operations
$2.82
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026